Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia : a Hokkaido Leukemia Net study

Miyashita, Naoki; Onozawa, Masahiro; Yoshida, Shota et al.

International journal of hematology, 2023, 118(1), 36-46

Permalink : https://hdl.handle.net/2115/93053

このアイテムのアクセス数:286件（2026-10-17 06:44 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
IJHM-D-22-00809_R3 pdf 1.59 MB 254

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/93053
タイトル
Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia : a Hokkaido Leukemia Net study
著者
Miyashita, Naoki ; Onozawa, Masahiro ; Yoshida, Shota ; Kimura, Hiroyuki ; Takahashi, Shogo ; Yokoyama, Shota ; Matsukawa, Toshihiro ; Hirabayashi, Shinsuke ; Fujisawa, Shinichi ; Mori, Akio ; Ota, Shuichi ; Kakinoki, Yasutaka ; Tsutsumi, Yutaka ; Yamamoto, Satoshi ; Miyagishima, Takuto ; Nagashima, Takahiro ; Ibata, Makoto ; Wakasa, Kentaro ; Haseyama, Yoshihito ; Fujimoto, Katsuya ; Ishihara, Toshimichi ; Sakai, Hajime ; Kondo, Takeshi ; Teshima, Takanori
著者名
Miyashita, Naoki
e-Rad_Researcher
70455632
著者名
Onozawa, Masahiro
著者名
Yoshida, Shota
著者名
Kimura, Hiroyuki
著者名
Takahashi, Shogo
著者名
Yokoyama, Shota
著者名
Matsukawa, Toshihiro
著者名
Hirabayashi, Shinsuke
著者名
Fujisawa, Shinichi
著者名
Mori, Akio
著者名
Ota, Shuichi
著者名
Kakinoki, Yasutaka
著者名
Tsutsumi, Yutaka
著者名
Yamamoto, Satoshi
著者名
Miyagishima, Takuto
著者名
Nagashima, Takahiro
著者名
Ibata, Makoto
著者名
Wakasa, Kentaro
著者名
Haseyama, Yoshihito
著者名
Fujimoto, Katsuya
著者名
Ishihara, Toshimichi
著者名
Sakai, Hajime
著者名
Kondo, Takeshi
e-Rad_Researcher
40284096
著者名
Teshima, Takanori
言語
英語
キーワード
AML
FLT3
NPM1
CEBPA bZIP
Hokkaido Leukemia Net (HLN)
North Japan Hematology Study Group (NJHSG)
発行日
2023-07-01
出版者
Springer
収録物名
International journal of hematology
巻(号)
118(1)
ページ
36-46
抄録
Mutation status of FLT3, NPM1, and CEBPA is used to classify the prognosis of acute myeloid leukemia, but its significance in patients with cytogenetically normal (CN) AML is unclear. We prospectively analyzed these genes in 295 patients with CN-AML and identified 76 (25.8%) FLT3-ITD, 113 (38.3%) NPM1 mutations, and 30 (10.2%) CEBPA biallelic mutations. We found that patients with FLT3-ITD had a poor prognosis at any age, while patients with CEBPA biallelic mutation were younger and had a better prognosis. FLT3-ITD and NPM1 mutations were correlated, and the favorable prognostic impact of being FLT3-ITD negative and NPM1 mutation positive was evident only in patients aged 65 years or more. For CEBPA, 86.7% of the patients with biallelic mutation and 9.1% of patients with the single allele mutation had in-frame mutations in the bZIP domain, which were strongly associated with a favorable prognosis. Multivariate analysis showed that age < 65 years, FLT3-ITD and CEBPA bZIP in-frame mutation were independent prognostic factors. The results suggest that analyzing these gene mutations at diagnosis can inform selection of the optimal intensity of therapy for patients with CN-AML.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
権利情報
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s12185-023-03567-1
PISSN
0925-5710
関連情報 (isVersionOf)
出版社版DOI
https://doi.org/10.1007/s12185-023-03567-1